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Abstract--Osteoblasts play a pivotal role during the bioresponse of bone to agents 
that stimulate bone n~sorption and/or inhibit bone formation including hormones, 
polypeptide growth factors, and cytokines. We examined the cytokines interleukin- 
1-beta (IL-lfl) and tumor necrosis factor-alpha (TNF-a) for their effects on osteob- 
lastic proliferation and development and expression of alkaline phosphatase and the 
osteoblast-specific protein osteocalcin in a mineralizing environment. Primary rat 
osteoblast-like cells (Y, OB) and osteoblastic cell lines derived from rat (ROS 17/2.8) 
and human (MG-63) osteosarcomas were studied. IL-I~ and TNF-c~ were chosen 
because of their critical importance during the host response to local inflammatory 
stimuli. Qualitatively similar two- to threefold inhibition of osteocalcin synthesis by 
IL-lfl and TNF-a wel~e observed in all three postconfiuent bone-forming model sys- 
tems. Because of the readily measurable concentrations of osteocalcin produced in 
our culture protocol, it was not necessary to enhance osteoblastic synthesis of osteo- 
calcin by supplementation with 1,25(OH)2-vitamin D3, a treatment which exerts 
pleiotropic effects on ~steoblasts. Under the constraints of our protocol, where alka- 
line phosphatase and mineralization were already elevated at the 14-day onset of 
treatment, neither of these phenotypic properties was sensitive to a three-day cytokine 
exposure. Differences were noted in proliferation, where only TNF-a stimulated 
DNA synthesis in ROB cells, while both cytokines stimulated MG-63 cells. IL-lfl 
and TNF-c~ failed to alter ROS 17/2.8 DNA synthesis except at the highest doses 
(25 pM IL-lfl and 1 nlVl TNF-a) where inhibition was observed. These results further 
support the view tha~ cytokine-mediated osteoblastic regulation can be relatively 
selective. 
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INTRODUCTION 
Cytokines are important determinants of osseous tissue homeostasis in health 
and disease. Investigation of interleukin-l-beta (IL-1/3) and tumor necrosis fac- 
tor-alpha (TNF-o0 in experimental bone models indicates that these cytokines 
depress osteoblastic bone formation (1, 2) and stimulate osteoclastic bone resorp- 
tion (3). At the cellular level, IL-loL and TNF-ot interact with osteoblasts (4, 5) 
and other cell types (6, 7) by surface receptors, and these interactions lead to 
profound alterations in osteoblast functions (8). For example, depending on the 
model system investigated, osteoblastic DNA and prostaglandin synthesis are 
stimulated by IL-1/3 and TNF-c~ (9-12). IL-1/3 and TNF-c~ are also known to 
depress osteoblast synthesis of collagen, alkaline phosphatase, and secretion and 
mineralization of the extraceUular bone matrix (10, 13, 14), although alkaline 
phosphatase stimulation has also been reported (15). At relatively high concen- 
trations, IL-1/3 and TNF-o~ cause osteoblasts to transmit a signal(s) that activates 
osteoclastic bone resorption (14, 16-18). The nature and mechanism of action 
of the osteoclast-activating factor(s) hypothesized in 1981 by Rodan and Martin 
(18) is not understood. 
Osteocalcin is another key osteoblastic product for which the expression is 
modulated by IL-1/3 and TNF-c~. Osteocalcin (bone Gla protein, BGP) is a 
vitamin K-dependent Ca 2 +-binding protein and is the most abundant noncolla- 
genous protein of the mineralized extracellular bone matrix where it resides on 
the surfaces of hydroxyapatite crystals (20, 21). While the exact role of osteo- 
calcin in bone formation or destruction is not known, there is evidence that after 
placement in the extracellular matrix by osteoblasts, osteocalcin may serve as 
an activator or chemoattractant for osteoclasts and/or their presumed monocytic 
precursors (22-24). As a specific differentiated product of mature osteoblasts, 
osteocalcin exhibits a highly conserved amino acid sequence, and is expressed 
relatively late in the developmental sequence of bone coincident with the onset 
of mineralization (21, 25, 26). The phenotypic expression of this protein is 
sensitive to numerous stimuli, including inhibitors of bone formation (e.g., 
corticosteroids) and growth factors and agents with bone resorbing activity (para- 
thyroid hormone, vitamin D) (21, 27). 
Thus, studies on osteocalcin synthesis may be useful in assessing the overall 
effects of cytokines and hormones on osteoblast metabolism. Unfortunately, 
progress in this area has been restricted because mammalian primary osteoblasts 
usually express relatively low levels of this marker protein under conventional 
culture conditions (1, 11, 13, 28-31). Recent improvements in rat osteoblast 
culture (32) (R. S. Taichman, S. E. Doleman, P. V. Hauschka, unpublished), 
patterned after the chick model system (26), have allowed sensitive monitoring 
of inhibitory effects on osteocalcin expression by osteoblasts in a mineralizing 
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e n v i r o n m e n t .  In  t h e  p r e s e n t  i n v e s t i g a t i o n ,  w e  a s s e s s e d  t h e  e f f ec t s  o f  I L - 1 B  a n d  
TNF-c~ o n  o s t e o c a l c i n  t 0 r m a t i o n  in t h r e e  o s t e o b l a s t  ce l l  c u l t u r e  s y s t e m s  w h e r e  
r e l a t i ve ly  h i g h  l e v e l s  o f  o s t e o c a l c i n  a re  p r o d u c e d  in v i t ro .  
M A T E R I A L S  A N D  M E T H O D S  
Cytokines. Recombinant human IL-l~3 (bioactivity: 5.0 x 108 units/mg) and human 
TNF-a (bioactivity: 1.0 x 107 units/mg) were obtained from Amgen Biologicals (Thousand Oaks, 
California). These particular cytokines were chosen for their relevance to bone biology in that 
IL-1/3 and TNF-o~ coincide ~r the majority of activity chromatically isolated from supernatants 
containing osteoclast activating activity (43). The concentrations of cytokines employed (IL-l~3: 
0.25-25 pM; TNF-~ 0.01-] .0 nM) are approximately equivalent to the bone-resorbing activity 
isolated from myeloma cells detected in bioassay (33) and below a concentration that, in preliminary 
investigations, caused the cells to round up and fail to exclude trypan blue stain (0.25 nM IL-I~ 
and 10.0 nM TNF-c~). 
Cell Lines and Culture Methods. Rat osteoblast-like (ROB) cells were isolated by enzymatic 
digestion of newborn rat calvaria as outlined by Cohn and Wong (34). Six sequential 20-min digests 
were performed on suture-free dissected calvarial fragments at 37~ in minimum essential medium 
(MEM) containing 2 mg/ml collagenase A (Boehringer Mannhein Biochemicals, Indianapolis, Indi- 
ana) and 0.005% trypsin (Gibco Laboratories, Grand Island, New York). Cells obtained from the 
third through sixth digests were pooled and plated in 24-well tissue culture plates (1.0 • 105 
celts/2 cm 2 well) in 0.5 ml Gf a-MEM (Gibco) containing 10% fetal bovine calf serum (FBS) with 
penicillin and streptomycin ~day 0). The medium was changed on days 5, 8, 11, and 14 and was 
additionally supplemented with fresh/3-glycerolphosphate and L-(+)-ascorbate to final concentra- 
tions of 10 mM and 50 tzg/rnl, respectively. On day 14 the ceils were washed twice with warm 
phosphate-buffered saline (PBS) and fresh culture medium containing 1% FBS and appropriate 
concentrations of IL-1/3 and TNF-c~ were added to quadruplicate wells. Cultures were maintained 
as before until day 17, at which time cell-free culture media were collected, centrifuged, and stored 
at - 2 0 ~  until assayed for ~steocalcin. The adherent cells were washed twice with cold PBS and 
prepared for analyses of total DNA, extracellular matrix-bound osteocalcin, mineralization of the 
extracellular matrix, and alkaline phosphatase activity. 
The MG-63 human o,,teosarcoma cell line (ATCC #CRL 1424) (1.0 • 105 cells/well) was 
cultured in 0.5 ml c~-MEM with Eafle's salts and 10% heat-inactivated FBS. The rat osteosarcoma 
cell line ROS 17/2.8 was generously provided by Dr. Robert Majeska (Mount Sinai Medical Center, 
New York, New York) and maintained in Ham's F12 medium with 5% FCS. Osteosarcoma cells 
were maintained as described above except that the serum concentrations were not altered during 
the 14- to 17-day experimental period. 
Osteocalcin Radioimmunoassay. Osteocalcin levels in culture supernatants and cell-associ- 
ated extracellular matrix were determined by a three-day nonequilibrium radioimmunoassay as 
previously described (35), employing the following antisera: goat anti-rat osteocalcin (first antibody) 
and donkey anti-goat (secon,] antibody) for determinations from ROB and ROS 17/2.8 ceil cultures; 
rabbit anti-bovine osteocalcin (first antibody: recognizes human osteocalcin) and goat anti-rabbit 
(second antibody) for the MG-63 cell line. Nonspecific binding of [t25I]osteocalcin (rat or bovine) 
was determined for each as.,~ay by omitting the primary antiserum from the reaction mixture. Data 
are reported either as total nanograms osteocalcin per culture, or as nanograms osteocalcin per 
microgram DNA. Because human and bovine osteocalcin are equally cross-reactive with our rabbit 
anti-bovine first antibody, the osteocalcin levels reported for the MG-63 cell line represent human 
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osteocalcin above the (approximately 15 ng/ml) bovine osteocalcin background originating from the 
10% FBS in the medium. To detect osteocalcin associated with the extracellular matrix, the cell 
layers were extracted with 0.5 M EDTA containing protease inhibitors (EPIC buffer) (35). 
Fluorometric Assay for Total DNA. m-Diaminobenzoic acid dihydrochloride (Sigma) was 
used to assay deoxyribose liberated by perchloric acid added to cell lysates (36). Samples were read 
on an Perkin-Elmer LS-5 fluorescence spectrometer at 408 nm (excitation) and 500 nm (emission) 
against a standard curve prepared with calf thymus DNA (Sigma) (assuming A26o = 0.025 for 1 
/zg/ml). Results are expressed as micrograms DNA per culture well. 
In Vitro Mineralization. Mineralization of ROB cell extracellular matrix was determined by 
the Von Kossa staining technique (3 % AgNO3) for matrix-associated phosphate (37). Individual 
black-staining mineralized nodules were counted under a dissecting microscope at 10 • and expressed 
as nodules per culture well. 
Alkaline Phosphatase Activity. Alkaline phosphatase activity in cultured cells was determined 
by the method of Reddi and Huggins (38). Following removal of culture media, cell layers were 
subjected to three freeze-thaw cycles, and sonicated in 200 #1 of assay buffer (0.15 M NaCI, 3 
mM NaHCO3, pH 7.4). Recovered samples (10/zl) were assayed for enzyme activity in 96-well 
plates with p-nitrophenylphosphate (Sigma) as a substrate in a total of 100/zl; after 15 min at 37~ 
the reaction was stopped with 100/~1 of 1 M NaOH and the absorbance was measured on an Dynatec 
MR700 ELISA plate reader with p-nitrophenol as a standard. Results are presented in units per 
microgram DNA, where 1 unit = 1 nmol p-nitrophenol liberated/15 min at 37~ 
Northern Hybridization Analysis. ROB cell cultures were initiated on day 0 by plating 3.75 
X 10 6 cells/75-cm 2 tissue culture flask containing 18.75 ml of medium. As described above, exper- 
imental conditions were established on day 14. Eighteen hours later, the ROB cell layers were 
washed twice with ice-cold PBS, solubilized in 7.5 M guanidine HCI (Sigma), and processed for 
total RNA as described by Sambrook et al. (39). Samples containing 20 /zg total cellular RNA 
(quantified by A26o/A280 and the orcinol reaction) were separated electrophoretically on formalde- 
hyde-agarose gels after the method of Thomas (40) and transferred to nitrocellulose (Schleicher and 
Schuell, Keene, New Hampshire) by capillary action. The cDNA probe for rat osteocalcin originally 
described by Celeste et al. (41) was generously supplied by Dr. A. J. Wozney (Genetics Institute, 
Cambridge, Massachusetts). The probe was labeled with [32p]dCTP by the random primer method 
(42). The blots were prehybridized and hybridized in 50% forrnamide; 5 • SSC; 50 mM sodium 
phosphate buffer, pH 6.5; 1% sodium dodecyl sulfate (SDS) at 45~ Following an overnight 
incubation, the membranes were washed for two 30-min washes at 65~ in 2 x SSC-0.1% SDS, 
0.5 x SSC-0.1% SDS, 0.1 • SSC-0.1% SDS and prepared for autoradiography. The resulting 
autoradiographs were quantified by scanning laser densitometry (LKB Ultrascan). 
Statistics. The Student's t test was utilized for the statistical analysis. 
R E S U L T S  
T h e  effects  o f  IL-1/3 and  TNF- t~  o n  os t eoca lc in  syn thes i s  and  the  deve l -  
o p m e n t  o f  ex t r ace l lu l a r  b o n e  m a t r i x  we re  s tud ied  in 14- to  17-day-o ld  os teob las t  
cu l tu res .  Th i s  p e r i o d  was  c h o s e n  b e c a u s e  it c o r r e s p o n d s  to the  exp re s s ion  o f  
the  os t eoca lc in  gene ,  sec re t ion  o f  o s t eoca lc in  in to  the  cu l ture  m e d i u m ,  and  
os t eoca lc in  i nco rpo ra t i on  in to  the  ce l l - a s soc ia t ed  ex t race l lu la r  mat r ix .  A t  this  
t ime ,  os teob las t i c  e x p r e s s i o n  o f  o the r  specif ic  ma rke r s  such  as o s t eopon t in ,  
o s t eonec t in ,  a lka l ine  p h o s p h a t a s e ,  and  m i ne r a l i z a t i on  is a lso  e l eva ted  (32).  
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Effects of IL-1t~ o~,. ROB Cell DNA and Osteocalcin Synthesis. Three 
concentrations of IL-1/3 (0.25, 2.5, 25 pM) were added to 14-day ROB cultures. 
Inhibition of osteocalcin synthesis was observed at all concentrations tested 
(Table 1). For example, control cultures produced a total of 228 _+ 6.3 ng 
osteocalcin/culture during days 14-17, whereas cultures treated with 25.0 pM 
IL-1/3 produced 77.2 _+ 11.6 ng osteocalcin/culture. The reduction in total 
osteocalcin was reflected in both the medium and cell-layer associated matrix 
fractions (Table 1, Figure 1). IL-1/3 had no significant effect on DNA synthesis 
(Table 1), suggesting that diminished osteocalcin synthesis is not merely a con- 
sequence of altered cellular replication. 
Effects of TNF-o~ or,: ROB Cell DNA and OsteocaIcin Synthesis. Table 1 
shows results of four representative experiments where ROB cells were exposed 
to TNF-o~. Increasing TNF-o~ concentrations reduced osteocalcin nanogram per 
microgram DNA levels at day 17 in both the medium (decreased 73 %) and cell- 
layer associated extracellalar matrix (decreased 59%) pools (Table i,  Figure 1). 
While inhibiting osteocMcin production, 0.01 and 0.1 nM TNF-a simulated 
ROB cell proliferation (Table 1). The total osteocalcin detectable in the cultures 
relative to control was reduced for each concentration of TNF-c~ tested (osteo- 
calcin, nanograms per well: control, 227 _ 6.3; 0.01 nM TNF<~, 154 + 28.9; 
0.1 nM TNF-cc 148 ___ i[3.9; 1.0 nM TNF-c~; 90.7 + 2.4). 
Effects of IL-1t3 and TNF-a on ROB Cell Osteocalcin mRNA. Total cel- 
lular RNA was isolated from ROB cells following an 18-h exposure to IL-1/3 
and TNF-a. As negative controls, ROB cells that were withheld from the osteo- 
calcin expression conditions [exposure to L-ascorbate (50 izg/ml) and/3-glycer- 
olphophate (10 mM) commencing on day 5] were included in the analysis. As 
shown in Table 1, message levels for osteocalcin were nearly four times greater 
in ROB cells grown in n~edium containing L-ascorbate and i3-glycerolphophate 
than in the negative controls. Incubation of ROB cells with IL-1/3 decreased the 
message for osteocalcin :letected by Northem hybridization analysis to levels 
below the basal levels of the negative control cells. Similar inhibition of the 
osteocalcin message occurred when ROB cells were exposed to 1.0 nM 
TNF-a (control, 2.58 densitometric units; 1.0 nM TNF-c~, 1.66 units). 
Effects of IL-113 and TNF-a on ROB Cell Alkaline Phosphatase Activ- 
ity. Kinetic studies indicated that there was a progressive rise in alkaline phos- 
phatase activity in control[ rat osteoblast cultures during the test period. At day 
14 the total alkaline phosi?hatase activity was 456 units/tzg DNA, increasing to 
944 units/t~g DNA at day 17, a 207% rise. At the concentrations tested, IL-I/3 
and TNF-c~ failed to influence the expression of this enzyme by ROB cells 
(Table 2). 
Effects of  IL-113 and TNF-a on ROB Cell Mineralized Nodule Forma- 
tion. Initial mineralization of the extracellular matrix by ROB cells occurs 
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IL-1 
o 
0 ,25 2.5 25 10 100 1000 
Cytokine [pM] 
Fig. 1 Effects of IL-I~ and TNF-c~ on osteocalcin expression by mt osteoblastic cells (ROB) in 
vitro. Primary cultures were established on day 0 from neonatal rat calvaria cells as described. From 
day 5 onward, cells were cultu red under mineralizing conditions in the presence of L-ascorbate and 
/3-glycerolphophate, with medium changes every three days. Cytokines were added at the indicated 
concentrations on day 14: IL-1/~ (0.25, 2.5, 25 pM); TNF-~x (10, 100, 1000 pM). Media and cell 
layers were harvested on day ] 7 for analysis of osteocalcin and DNA. Values are expressed as ng 
osteocalcin/tlg DNA. Solid bar = medium osoteocalcin; open bar = cell layer osteocalcin; Total 
bar height = total osteocalcin per culture; error bars shown separately for medium and total osteo- 
calcin indicate means + standard deviation (N = 4); *significant difference from control, P _< 
0.05. 
Table 2. Effects of IL-1B and TNF-cz on ROB 
Cell Alkaline Phosphatase Activity ~ 
Alkaline phosphatase 
Condition (units//~g DNA) 
Con'xol 943.7 + 120 
IL-1 0,25 pM 752.5 + 120 
IL-1 2,50 pM 1114.0 + 164 
IL-1 25.0 pM 1072.7 _+ 164 
TNF 0.01 nM 912.8 _+ 49.0 
TNF 0.10 nM 1073.1 + 120.0 
TNF 1.00 nM 980.6 + 126.0 
o RCB cell cultures were established and treated 
as in Table 1. Data are means (N = 4) + 
sta~ldard deviation representing the 
p-~itrophenol liberated by homogenates from 
individual 4-cm z wells on day 17 (1 unit = 1 
nmol/15 min at 37~ There were no signif- 
icaat differences from the control. 
in dense  reg ions  o f  the cell  layer.  Si lver  s taining conver t s  these  nodular  ca lc ium 
phospha t e  depos i t s  to s i lver  phospha te ,  w h i c h  b e c o m e  b lack  upon  exposure  to 
l ight.  Such nodu les  are readi ly counted .  Dur ing  the  14- to 17-day per iod,  the 
n u m b e r  o f  minera l i zed  ~aodules increase  f rom 104 + 9 nodules /cu l tu re  to 163 
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Table 3. Effects of IL-1/3 and TNF-c~ on 
ROB Cell Mineralized Nodule Formation a 
Condition Nodules/culture 
Control 163.3 + 14.6 
IL-1/3 0.25 pM 218.7 __+ 23.9 
IL-1/3 2.50 pM 187.3 + 22.8 
IL-1/3 25.0 pM 193.0 __+ 15.6 
TNF-ct 0.01 nM 207.0 + 20.2 
TNF-c~ 0.10 nM 189.3 ___ 31.7 
TNF-c~ 1.00 nM 174.0 + 16.5 
aROB cell cultures were established and 
treated as in Table 1. Data are means (N 
= 4) 4- standard deviation representing the 
number of silver-stained mineral nodules 
per4-cm 2 well on day 17 (1 unit = 1 nmol/ 
15 min at 37~ there were no signifcant 
differences from the control. 
Table 4. Effects of IL-1/3 and TNF-a on ROS 1712.8 Cells a 
Osteocalcin DNA Osteocalcin 
Condition (ng/ml medium) (/~g/well) _(ng//xg DNA) 
Exp 1 
Control 96.4 _+ 9.80 7.37 • 0.58 13.0 ___ 1.96 
IL-1/3 0.25 pM 99.7 + 5.40 8.05 + 0.60 12.4 + 0.55 
IL-1/3 2.50 pM 58.3 + 5.90 b 7.45 + 0.45 7.69 + 0.95 b 
IL-I/~ 25.0 pM 45.0 + 14.8 b 6.35 _+ 0.20 b 7.17 + 2.60 b 
Exp 2 
Control 96.0 + 12.4 7.65 • 0.49 12.4 + 2.27 
TNF-~ 0.10 nM 57.0 + 4.1 b 8.12 4- 0.38 b 7.14 _+ 0.62 b 
TNF-a 1.00 nM 24.7 + 9.5 b 5.72 4- 0.49 b 4.53 + 0.22 b 
~Data are means (N = 4) + standard deviation. 
bSignificantly different from controls: P _< 0.05. 
+ 15 nodules /cu l tu re .  IL-1/3 and  TNF-c~ had  no d iscern ib le  effect  on minera l i zed  
nodule  fo rmat ion  dur ing  this interval  (Table  3). 
Effects of IL-1{3 and TNF-~ on Osteocalcin and DNA Synthesis by ROS 
17/2.8 and MG-63 cells. To conf i rm that  the inhibi tory effects  o f  IL-1/3 and 
T N F - a  on  ROB cell  os teoca lc in  syn thes i s  is a genera l i zed  feature o f  the os teob-  
last  pheno type ,  two  os t eosa rcomas  cell  l ines were  s tudied.  Both the rat 17/2.8 
and the h u m a n  M G - 6 3  were  found  to p roduce  modera t e  levels  o f  os teoca lc in  
us ing s imi lar  culture condi t ions ,  s l ightly modi f i ed  for  the par t icular  g rowth  
Effects of IL-11~ and TNF-ct 
Table 5. Effects of IL-lC] and TNF-a on MG-63 Cells" 
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Osteocalcin DNA Osteocalcin 
Condition (ng/ml medium) (#g/well) (ng//zg DNA) 
Control 46.1 +_ 5.3 14.6 + 1.6 3.20 + 0.6 
IL-113 0.25 pM 40.5 + 4.2 15.4 + 5.0 2.81 + 0.6 
IL-1/3 2.50 pM 39.4 + 5.7 18.1 _.% 1.6 2.19 + 0.4 b 
IL-1/3 25.0 pM 36.1 + 3 . 3  t' 23.9 + 0.7 h 1.51 + 0.1 h 
TNF-~ 0.01 nM 41.7 +_ 2.1 27.3 + 1.6 ~' 3.33 + 0.4 
TNF-e~ 0.10 nM 40.4 + 5.5 24.9 _+ 1.2 b 2.55 _ 0,4 
TNF-~ 1.00 nM 31.7 _ 1.3 b 14.6 + 1.6 1.22 + 0.1 ~' 
"Data are means (N = 4) _+ s:andard deviation. 
hSignificantly different from controls: P < 0.05. 
requirements of  each tumor type. The medium was supplemented with h-ascor- 
bate and B-glycerolphosphate,  but no addition of  1,25(OH)2-vitamin D 3 was 
required to elevate osteocalcin levels into the measurable range. As presented 
in Tables 4 and 5, IL-113 and TNF-c~ inhibited the synthesis of  osteocalcin by 
ROS 17/2.8 and MG-63 cells. The effects of  the cytokines on DNA synthesis 
were variable. For  ROS 17/2.8 cells, IL-113 and TNF-t3 failed to alter DNA 
synthesis except at the greatest concentrations of  IL-1/3 (25 pM) and TNF-~  (1 
nM), where D N A  declined 14% and 25% respectively (Table 4). For  MG-63 
cells,  IL-113 at 0 .25-25 pM and TNF-o~ at 0.01 and 0.1 nM stimulated DNA 
synthesis by up to 87 % (Table 5). 
D I S C U S S I O N  
Effects of  IL-1/3 and TNF-c~ on osteoblastic bone formation were studied 
in vitro by monitoring the osteoblast-specific protein osteocalcin and other dif- 
ferentiated functions. These particular cytokines were examined because they 
are of  crucial importance during the hosts response to local inflammatory stimuli. 
IL-1/3 and TNF-c~ are relevant to bone biology in that they coincide with the 
majority of  activity chrematographical ly isolated from conditioned media con- 
taining osteoclast activating activity (43). 
IL-1/3 inhibits the synthesis of  osteocalcin by normal rat osteoblastic cells 
(ROB) and by human (MG-63) and rat (ROS 17/2.8) osteosarcoma cell lines. 
For  the range o f  concentrations investigated (0 .25-25.0  pM IL-1r ROB cell 
osteocalcin synthesis was inhibited up to about threefold, while the osteosarcoma 
lines were inhibited about twofold.  In the case of  ROB cells, the reductions in 
osteocalcin levels obsereed by radioimmunoassay o f  the secreted protein are 
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strongly correlated with decreased steady-state levels of osteocalcin mRNA from 
Northern hybridization analysis (Table 1). This is consistent with the possibility 
that TNF-a (44) and IL-1/3 (45) may regulate osteocalcin synthesis by transcrip- 
tional control. The depression of osteocalcin synthesis was not directly associ- 
ated with an altered rate of division of the normal rat osteoblast-like cells. This 
is unusual in that many polypeptide growth factors (such as TGF-/3, PDGF, 
aFGF, bFGF, IGF-I, and IGF-iI) stimulate the proliferation of quiescent osteo- 
blast populations in vitro. In most cases investigated, osteocalcin biosynthesis 
decreases in response to mitogens. (27, 46, 47). 
TNF-c~ inhibits osteocalcin synthesis by primary ROB cells and the 
MG-63 and ROS 17/2.8 osteosarcoma cell lines. The reduction in osteocalcin 
synthesis is relatively selective, as the cytokine was without effect on other 
osteoblast phenotypic markers such as alkaline phosphatase activity and miner- 
alized nodule formation. Similar specificity of TNF-a inhibition on osteocalcin 
synthesis was reported for primary human osteoblasts and may simply indicate 
the exquisite sensitivity of osteocalcin to perturbation by cytokines (29). Our 
Northern hybridization analysis of steady-state osteocalcin mRNA levels in ROB 
cells following exposure to IL-1/3 (0.25-25 pM) and 1 nM TNF-o~ suggests that 
the reduction in osteocalcin synthesis is due to reduced transcriptional rate and/ 
or reduced stability of the osteocalcin mRNA. Nanes et al. (44) made similar 
observations using ROS 17/2.8 cells. Recent studies of the regulatory elements 
in the osteocalcin gene have shown AP-1 sites to which jun-fos protein com- 
plexes may bind (45, 48). IL-1/3 effects on T cells (49) and TNF-c~ effects on 
fibroblasts (50) reportedly involve AP-1 related sites in other genes. 
IL-1/3 and TNF-a are known to stimulate bone resorption (2, 3, 33). This 
action may be accomplished by direct effects of IL-1/3 on osteoclast precursors 
and mature osteoclasts (43, 53, 54) or by indirect effects involving osteoblastic 
mediation by PGE2, secreted proteinases, and other factors. (5, 11, 16-18, 31, 
55-57). An additional regulatory loop requiring further investigation is osteo- 
calcin-osteoclast interactions. Osteocalcin has been shown to be a chemoattract- 
ant for monocytic osteoclast precursors (22) and osteoclasts (24). Bone particles 
deficient in osteocalcin are poorly resorbed relative to normal bone (23). A 
hidden benefit for the host may be derived from the selective inhibition of 
osteocalcin by cytokines. Turning off osteocalcin synthesis, while associated 
with a reduction in bone formation, may limit the recruitment of osteoclasts to 
inflammatory sites (51). 
We have observed similar inhibitory effects of IL-1/3 and TNF-a on osteo- 
calcin synthesis in three osteoblastic cell types. Differences were noted for cyto- 
kine effects on DNA synthesis. Only TNF-a stimulated DNA synthesis in ROB 
cells (Table 1), while both cytokines stimulated DNA synthesis by MG-63 cells 
(Table 5). Under the constraints of the day 14-17 protocol, ROS 17/2.8 cells 
did not show increased DNA synthesis in response to IL-1/3 and TNF-a (Table 
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4). The healing response of osteoblasts to wounding frequently involves prolif- 
eration of osteoprogenitor (preosteoblastic) cells. Subsequent to the proliferative 
events, a period of deposition and maturation of new extracellular matrix ensues. 
It has been observed that both IL-1/3 and TNF-c~ inhibit markers of new bone 
formation (alkaline phosphatase and mineralized nodules), particularly if added 
early to developing osteoblast cultures (52). However, in our study of postcon- 
fluent normal ROB cells, the only formation marker inhibited is osteocalcin, 
and only TNF-ot stimulates osteoblastic replication. This suggests that there may 
be different mechanisms by which the two cytokines IL-1/3 and TNF-e~ inhibit 
bone formation. 
IL-1/3 and TNF-ce are known to have similar effects on osteocalcin synthesis 
by ROS 17/2.8 cells and primary human osteoblast-like cells with in the first 
week of culture (1, 13, 29). The present study extends these observations to 
include the effects of the cytokines on postconfluent cultures of both normal and 
transformed osteoblasts. The time distinction is important, because elevated 
osteocalcin synthesis in vitro does not commence until the two- to three-week 
period when primary cell.'; have elaborated an extensive extracellular collagenous 
matrix, which can be induced to mineralize with j3-glycerolphosphate (32, 36, 
37). Importantly, several commonly utilized osteoblast culture protocols actually 
diminish osteocalcin synthesis: (1) the use of passaged primary cells (32); (2) 
charcoal treatment of serum to remove osteocalcin and vitamin D backgrounds 
(39, 51); and (3) exposure of preconfluent osteoblast cultures to L-ascorbate (32, 
51). In addition, certain lots of serum were nonpermissive for the inhibitory 
effects of IL-I{3 and TNF-a on osteocalcin synthesis by ROB, MG-63, and ROS 
17/2.8 cells (51). In light of the relatively high levels of osteocalcin achieved 
in the osteoblast cultures in this study, it was not necessary to enhance osteo- 
calcin synthesis by supplementing with 1,25(OH)2-vitamin D3, a treatment that 
would cause pleiotropic effects including diminished matrix collagen synthesis. 
This reduces the complexity compared to human osteoblast culture systems 
where effects O f cytokines on osteocalcin expression have been assessable only 
if studied in the presence; of high concentrations of 1,25(OH)2-vitamin D 3 (11, 
12, 29, 31). While these differences in culture methods are largely methodo- 
logical, for osteocalcin s:r the differences are hardly trivial, underscoring 
the distinctions between available models systems for studying bone formation. 
The present ROB cell calture model of bone formation in vitro would likely 
correspond to the effects IL-1/3 and TNF-a on mature osteoblasts in vivo at a 
site of inflammation, rather than the effects of these cytokines during initial bone 
development. 
Tissue destruction in arthritis, osteomyelitis, and periodontal disease may 
occur as a direct result of bacterial attack and/or as a by-product of the response 
of immunocompetent cells to exogenous microbiological and pathological stim- 
uli. In the past, immunocompetent cells have been defined as lymphocytes, 
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granulocytes, and macrophages; however, recent findings indicate that osteo- 
blasts can synthesize cytokines (including IL-1, TNF, M-CSF, GM-CSF, 
IL-6) (30, 53, 55, 58-60) and may also function as antigen-presenting cells 
under appropriate conditions (61). These insights have begun to reshape the 
hypothesis regarding the role of various inflammatory and resident cells during 
local immunopathologic responses. In this context, the effects of injury to 
osteoblasts is of critical importance for our understanding of the mechanisms of 
bone destruction. Autocrine regulation of osteoblast metabolism by osteoblast- 
synthesized cytokines and growth factors undoubtedly plays an important role 
(27, 28, 46, 53, 62, 63). Clearly, the mitogenic and phenotypic response of 
osteoblastic cells will depend on the constellation of bioactive factors in their 
environment, as well as their membrane-receptor status for each of these multiple 
agents. Fundamental investigation of responses to endogenous and exogenous 
cytokines in the context of the inflammatory response is needed. Here we pro- 
vide evidence for the ability of IL-1/3 and TNF-c~ to inhibit a major differentiated 
function of osteoblasts, osteocalcin synthesis, at a time when the cells are rel- 
atively quiescent and producing a mineralized matrix. This inhibition of osteo- 
calcin appears relatively selective in that alkaline phosphatase expression and 
mineralized nodule parameters were unaffected during the test period. 
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